Shopping Cart
- Remove All
Your shopping cart is currently empty
Anti-ADAR Antibody (1G868)
😃Good
Catalog No. TMAH-00028
Anti-ADAR Antibody (1G868) is an antibody targeting ADAR. Anti-ADAR Antibody (1G868) can be used in ELISA,IHC.
Anti-ADAR Antibody (1G868)
Anti-ADAR Antibody (1G868)
😃Good
Catalog No. TMAH-00028
Anti-ADAR Antibody (1G868) is an antibody targeting ADAR. Anti-ADAR Antibody (1G868) can be used in ELISA,IHC.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 50 μL | $208 | 7-10 days | |
| 100 μL | $347 | 7-10 days |
Add to Cart
Add to Quotation
Bulk & Custom
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
View MoreResource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
| Description | Anti-ADAR Antibody (1G868) is an antibody targeting ADAR. Anti-ADAR Antibody (1G868) can be used in ELISA,IHC. |
| Ig Type | Rabbit IgG |
| Clone | 1G868 |
| Reactivity | Human |
| Verified Activity | IHC image of TMAH-00028 diluted at 1:100 and staining in paraffin-embedded human brain tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB. |
| Application | |
| Recommended Dose | IHC:1:50-1:200. |
| Antibody Type | Monoclonal |
| Subcellular Localization | [Isoform 1]: Cytoplasm. Nucleus.; [Isoform 5]: Cytoplasm. Nucleus. Nucleus, nucleolus. |
| Tissue Specificity | Ubiquitously expressed, highest levels were found in brain and lung. Isoform 5 is expressed at higher levels in astrocytomas as compared to normal brain tissue and expression increases strikingly with the severity of the tumor, being higher in the most ag |
| Construction | Recombinant Antibody |
| Purification | Affinity-chromatography |
| Appearance | Liquid |
| Formulation | Phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
| Research Background | Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication. |
| Conjucates | Unconjugated |
| Immunogen | A synthetic peptide: Human ADAR1 |
| Antigen Species | Human |
| Gene Name | ADAR |
| Gene ID | |
| Uniprot ID | |
| Biology Area | Epigenetics and Nuclear Signaling, Microbiology |
Stability & Storage
| Stability & Storage | Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. |
| Transport | Shipping with blue ice. |
Calculator
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . 
Sci Citations
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Anti-ADAR Antibody (1G868) | purchase Anti-ADAR Antibody (1G868) | Anti-ADAR Antibody (1G868) cost | order Anti-ADAR Antibody (1G868)
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.